Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22850860 | 0.81 | MAPT (0.43) | L3MBTL1MAPTTDP1MAPK1MAPK14 | |
| SCHEMBL24930498 | 0.81 | MPO (0.50) | L3MBTL1MAPTTDP1MAPK1MAPK14 | |
| SCHEMBL2415179 | 0.81 | APP (0.53) | MAPTSMN1; SMN2RAB9ANPC1MAOB | |
| SCHEMBL15577719 | 0.81 | L3MBTL1 (0.47) | L3MBTL1MAPTTDP1MAPK1MAPK14 | |
| SCHEMBL31394965 | 0.80 | SMN1; SMN2 (0.50) | L3MBTL1MAPTTDP1MAPK1MAPK14 | |
| SCHEMBL6639600 | 0.79 | MAPT (0.44) | L3MBTL1MAPTTDP1MAPK1MAPK14 | |
| SCHEMBL3947830 | 0.79 | SMN1; SMN2 (0.58) | L3MBTL1MAPTTDP1MAPK1MAPK14 | |
| SCHEMBL20616563 | 0.79 | HTR1A (0.47) | L3MBTL1MAPTTDP1MAPK1SMN1; SMN2 | |
| SCHEMBL8695151 | 0.79 | USP28 (0.43) | L3MBTL1MAPTTDP1MAPK1MAPK14 | |
| SCHEMBL31339028 | 0.78 | SYK (0.42) | L3MBTL1MAPTTDP1MAPK1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111217811-B | Fused tricyclic compounds and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-110903284-B | Fused tricyclic compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-111217811-A | Fused tricyclic compound and application thereof in medicines | 广东东阳光药业有限公司 | 2020-06-02 | — | — | CN | disclosed |
| CN-110903284-A | Fused tricyclic compound and application thereof in medicines | 广东东阳光药业有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-9932323-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932323-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932323-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-20 | — | — | US | disclosed |
| WO-2014043252-A2 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-03-20 | — | — | WO | disclosed |
| EP-2542077-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | Merck Sharp & Dohme Corp. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005744-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-01-03 | — | — | US | disclosed |
| US-20130005744-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-01-03 | — | — | US | disclosed |
| US-20130005744-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-01-03 | — | — | US | disclosed |
| WO-2011109261-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-1396487-B1 | PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-7196080-B2 | Respiratory system disordeers; chronic obstructive pulminary disease | ASTELLAS PHARMA INC. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20040192701-A1 | Phenlypyridine carbonyl piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2004-09-30 | — | — | US | disclosed |
| EP-1396487-A1 | PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | XDH, DPYD, P4HA1 | L3MBTL1 4001/4885MAPT 4512/4885TDP1 82/4885 |
| US-20040192701-A1 | Phenlypyridine carbonyl piperazine derivative | PDE5A, PDE4A, PDE3B | L3MBTL1 2498/4885MAPT 4798/4885TDP1 257/4885 |
| US-20130005744-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | COMT, PNMT, TPMT | L3MBTL1 1517/4885MAPT 220/4885TDP1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.